Cargando…
UGT1A1 Polymorphism for Irinotecan Dose Escalation in Patients with BRAF-Mutated Metastatic Colorectal Cancer Treated with First-Line Bevacizumab and FOLFIRI
BACKGROUND: Patients with metastatic colorectal cancer (mCRC) and BRAF V600E mutation have a poor prognosis, with a median progression-free survival (PFS) of only 5–7 months after initial therapy. The current standard first-line chemotherapy for these patients includes FOLFOX or FOLFIRI plus bevaciz...
Autores principales: | Hsieh, Yi-Chien, Chang, Tsung-Kun, Su, Wei-Chih, Huang, Ching-Wen, Tsai, Hsiang-Lin, Chen, Yen-Cheng, Li, Ching-Chun, Chen, Po-Jung, Yin, Tzu-Chieh, Ma, Cheng-Jen, Wang, Jaw-Yuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7972843/ https://www.ncbi.nlm.nih.gov/pubmed/33777142 http://dx.doi.org/10.1155/2021/6686517 |
Ejemplares similares
-
Comparison of UGT1A1 Polymorphism as Guidance of
Irinotecan Dose Escalation in RAS Wild-Type Metastatic Colorectal
Cancer Patients Treated With Cetuximab or Bevacizumab Plus FOLFIRI as the First-Line
Therapy
por: Tsai, Hsiang-Lin, et al.
Publicado: (2022) -
Clinical Outcomes of Patients with Peritoneal Metastasis-Only Colorectal Cancer Treated with First-Line Bevacizumab and FOLFIRI Through Irinotecan Dose Escalation According to UGT1A1 Polymorphism: Compared to Liver Metastasis-Only, and Lung Metastasis-Only
por: Li, Ching-Chun, et al.
Publicado: (2022) -
Clinical Implication of UGT1A1 Promoter Polymorphism for Irinotecan Dose Escalation in Metastatic Colorectal Cancer Patients Treated with Bevacizumab Combined with FOLFIRI in the First-line Setting()()
por: Lu, Chien-Yu, et al.
Publicado: (2015) -
FOLFIRI and regorafenib combination therapy with dose escalation of irinotecan as fourth-line treatment for patients with metastatic colon cancer according to UGT1A1 genotyping
por: Lu, Chien-Yu, et al.
Publicado: (2014) -
Prospective analysis of UGT1A1 promoter polymorphism for irinotecan dose escalation in metastatic colorectal cancer patients treated with bevacizumab plus FOLFIRI as the first-line setting: study protocol for a randomized controlled trial
por: Yeh, Yung-Sung, et al.
Publicado: (2016)